oPEN LABEL PHASE 1 STUDY TO ASSESS THE MAXIMUM TOLERATED DOSE, PHARMACOKINETICS, AND SAFETY OF iXAZOMIB ADMINITERED INTRAVENOUSLY TO PEDIATRIC PATIENTS AGED 0 TO LESS THAN 18 YEARS WITH RELAPSE RELAPSE OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA, WITH OR WITHOUT EXTREMEDULLARY DISEASSE, OR RELAPSE OR REFRACTORY LYMPHOBLASTIC LYMPHOMA.